Adele Ratti

Adele Ratti

Auto-generated profile, based on publicly available information

Adele Ratti

Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in Neurology Genetics
Verified
Journal Article
Open access
CLChristian Laurini
Christian Laurini
FDFEDERICA RACHELE DANTI
FEDERICA RACHELE DANTI
Massimo RussoMassimo Russo
Massimo Russo
STStefano Tozza
Stefano Tozza
Sara MassuccoSara Massucco
Sara Massucco
SPStefano Previtali
Stefano Previtali
Myelin protein zero (MPZ)–related neuropathies include demyelinating CMT1B and later-onset axonal forms (CMT2I/J). CMT1B pathogenic variants act through gain-of-function, destabilizing MPZ and activating the unfolded protein response (UPR), or loss-of-function, disrupting MPZ homomeric interactions in myelin. This study investigates early-onset (<18 years) CMT1B due to MPZ variants in a large Italian cohort, shedding light on clinical progression and genotype-phenotype correlations, with relevance to emerging UPR-targeted therapies. We analyzed cross-sectional clinical and genetic data from 75 patients across 7 Italian centers. MPZ variants were categorized as destabilizing or non-destabilizing based on published data. To explore the relationship between the degree of protein destabilization and clinical severity, missense variants were evaluated for stability alterations using the DUET online tool, with negative ∆∆G values indicating greater destabilization. Statistical correlations between clinical and molecular features were assessed. This study presents a comprehensive clinical characterization of one of the largest cohorts of early-onset MPZ-related neuropathies reported to date. The Charcot-Marie-Tooth Examination Score (CMTES) correlated with age at assessment (rs = 0.56; p < 0.001), suggesting disease progression in this cohort. Destabilizing variants were associated with earlier onset (p < 0.001), upper limb involvement (p < 0.001), impaired ambulation (p < 0.01), scoliosis (p < 0.01), and faster progression as measured by CMTES/age (0.24 vs 0.11 CMTES/year). After excluding the c.245A>C, p.Y82S outlier (highly destabilizing but not UPR-activating), ∆∆G values showed significant correlations with age at onset (rs = 0.54, p = 0.030), CMTES (rs = −0.82, p < 0.001), and progression (rs = −0.60, p = 0.032). Stratification of MPZ variants into destabilizing and non-destabilizing is crucial for predicting severity and prognosis and tailoring therapeutic strategies. This approach has significant implications for upcoming UPR-modulating treatments and underscores the necessity of integrating molecular and clinical insights for optimal patient care.

1 November 2026 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
LBLuca Bosco
Luca Bosco
CLChristian Laurini
Christian Laurini
LALuca Angelini
Luca Angelini
MBMarco Bosco
Marco Bosco
ARAdele Ratti
Adele Ratti
UCUbaldo Del Carro
Ubaldo Del Carro

18 August 2026 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
CGChiara Gallo
Chiara Gallo
CFCarla Fasano
Carla Fasano
AFAngelo Fonseca
Angelo Fonseca
YFYuri Falzone
Yuri Falzone
DCDario Cocito
Dario Cocito
TGthe Italian CIDP and MMN Database Study Groups
the Italian CIDP and MMN Database Study Groups
Background: The definition of motor conduction block (CB) and proximal temporal dispersion (TD) for the diagnosis of CIDP and MMN remains debated, particularly regarding whether CB should be based on amplitude or area reduction, and whether proximal TD is best assessed using negative peak or total CMAP duration. Methods: Nerve conduction waveforms from 106 CIDP, 87 MMN, and 234 controls were analyzed. Motor CB was defined by ≥ 30%, ≥ 40%, or ≥ 50% amplitude or area reduction. Proximal TD was defined as a ≥ 30% increase in negative peak duration, total CMAP duration, or either criterion. Sensitivity, specificity, and inter‐rater reliability were analyzed. Results: Across both CIDP and MMN, a ≥ 30% reduction in CMAP amplitude showed diagnostic performance comparable to area‐based CB definitions and outperformed higher cutoff values. Requiring CB in multiple nerves increased specificity but reduced sensitivity. For proximal TD, negative peak duration was the most robust single parameter. Total CMAP duration identified additional abnormalities and, when combined with negative peak duration, improved diagnostic sensitivity in both disorders while maintaining high specificity. Total CMAP duration demonstrated good inter‐rater agreement at the patient level. CMAP morphology showed substantial overlap between CIDP and MMN and limited discriminatory value. Conclusions: A ≥ 30% reduction in CMAP amplitude can be used as a universal definition of motor CB in both CIDP and MMN, providing diagnostic performance comparable to area‐based criteria with greater simplicity. In addition, proximal TD assessed using total CMAP duration may represent a complementary electrophysiological criterion in both disorders.

4 November 2026 in Neurology Clinical Practice
Verified
Journal Article
Closed access
PDF file
ARAdele Ratti
Adele Ratti
LBLuca Bosco
Luca Bosco
CLChristian Laurini
Christian Laurini
LALuca Angelini
Luca Angelini
BSBenedetta Sorrenti
Benedetta Sorrenti
YFYuri Matteo Falzone
Yuri Matteo Falzone
Purpose of ReviewCranial neuropathies are a frequent reason for neurologic consultation, yet they remain diagnostically challenging because of a broad etiologic spectrum and overlapping clinical pr...

15 November 2026 in Muscle & Nerve
Verified
Journal Article
Closed access
ARAdele Ratti
Adele Ratti
MYMona Rita Yacoub
Mona Rita Yacoub
ACAlessandra Criscuoli
Alessandra Criscuoli
GGGiovanni Gaiera
Giovanni Gaiera
NANicoletta Anzalone
Nicoletta Anzalone
SPStefano Previtali
Stefano Previtali